IASLC 2016 Multidisciplinary Symposium in Thoracic Oncology
September 22-24, 2016
Chicago Marriott Downtown Magnificent Mile
Chicago, IL

Steering Committee: Fred R. Hirsch, MD, PhD, Everett Vokes, MD

Program Chairs: Jyoti D. Patel, MD, Heather Wakelee, MD

Thursday, September 22, 2016

4:00pm - 6:00pm  Registration

6:00pm - 6:05pm  Opening Ceremony and Welcome
                 F.R. Hirsch, E. Vokes, J. Patel

6:05pm - 6:35pm  “Immunotherapy in Lung Cancer”  Julie Brahmer

6:35pm - 6:55pm  “Looking Forward-Immunology Approach in 2020”  Roy Herbst

6:55pm - 7:15pm  “Understanding of Tumor Immunology”  Scott Antonia

7:15pm - 7:20pm  Patient Advocate Perspective  Chris Draft

7:30pm - 9:00pm  Dinner/Symposium Sponsored by Astra Zeneca
Friday, September 23, 2016

7:00am - 5:00pm  Registration

7:00am - 8:00am  Breakfast symposium Sponsored by AstraZeneca

7:00am - 8:00am  Breakfast in the registration area

8:00am - 8:05am  Welcome  

8:00am - 8:25am  Prevention/Screening  
David Yankelevitz

8:25am - 8:45am  Novel Diagnostics in Interventional Pulmonology  
Charles Powell

8:45am - 9:00am  Targeted Radiation Therapy  
Matt Harkenrider

9:00am - 9:20am  Targeted Systemic Therapy  
Karen Kelly

9:20am - 9:35am  Managing Unique Toxicities: Immune  
Nate Pennell

9:35am - 9:50am  Small Cell Updates  
Charlie Rudin

9:50am - 10:05am  Mesothelioma Updates  
Hedy Kindler

10:05am - 10:30am  Break

10:30am - 12:00pm  Highlighted Oral Session 1

10:30am - 10:40am  Oral01.01 A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry  
David Rimm

10:40am - 10:50am  Oral01.02 Biopsies in Initial Diagnosis of Non-Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy  
Maen Hussein

10:50am - 11:05am  Discussant  
Leora Horn

11:05am - 11:15am  Panel Q & A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15am - 11:25am</td>
<td>Oral01.03</td>
<td>CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced NSCLC.</td>
<td>Scott J. Antonia</td>
</tr>
<tr>
<td>11:25am - 11:35am</td>
<td>Oral01.04</td>
<td>Phase II Trial of Atezolizumab for Patients with PD-L1 Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results</td>
<td>Heather Wakelee</td>
</tr>
<tr>
<td>11:35am - 11:50am</td>
<td>Discussant</td>
<td></td>
<td>Jyoti Patel</td>
</tr>
<tr>
<td>11:50am - 12:00pm</td>
<td>Q + A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td></td>
<td>Lunch Symposia Sponsored by Merck and Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td></td>
<td>Lunch in the registration area</td>
<td></td>
</tr>
<tr>
<td>1:30pm - 2:15pm</td>
<td></td>
<td>Session 1A/1B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breakout Session 1A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiation Oligometastic Disease</td>
<td></td>
<td>Daniel Gomez</td>
</tr>
<tr>
<td></td>
<td>IMRT vs. Proton therapy with concurrent chemotherapy in NSCLC</td>
<td></td>
<td>Melenda Jeter</td>
</tr>
<tr>
<td></td>
<td>Breakout Session 1B</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgery Novel Techniques</td>
<td></td>
<td>Mac DeCamp</td>
</tr>
<tr>
<td></td>
<td>Tranimodality vs BiModality Therapy in State III Disease</td>
<td></td>
<td>Eric Vallieres</td>
</tr>
<tr>
<td>2:15pm - 3:00pm</td>
<td></td>
<td>Session 2A/2B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breakout Session 2A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next generation sequencing of circulating tumor DNA for tumor genotyping and monitoring</td>
<td></td>
<td>Max Diehn</td>
</tr>
<tr>
<td></td>
<td>The role of rapid targeted assays for tumor and plasma genotyping</td>
<td></td>
<td>Geoff Oxnard</td>
</tr>
<tr>
<td></td>
<td>Immunotherapy Biomarkers</td>
<td></td>
<td>Fred R. Hirsch</td>
</tr>
</tbody>
</table>
Breakout Session 2B

Medical Oncology/Clinical Trials – Planning Trials that will be relevant in 2020
Suzanne Dahlberg

Rational Trial Design that will Impact Patient Care
David Gandara

Patient Centered Clinical Trials
Kim Norris

3:00pm - 3:30pm  Break

3:30pm - 4:45pm  Year in Review

3:30pm - 3:45pm  ALK Updates
Alice Shaw

3:45pm - 4:00pm  Disparities in Lung Cancer
Joy Feliciano

4:00pm - 4:15pm  Meeting Updates – ASCO
Heather Wakelee

4:15pm - 4:45pm  Debate: Immunotherapy vs Chemotherapy as first line
Pro
Phil Bonomi
Con
John Heymach

4:45pm - 5:05pm  Poster Discussion

4:45 - 4:55pm

Poster Discussant:  Stacie Levine

Highlighted Posters:

PS01.01 Simulation in the Management of EGFR-Mutated Advanced NSCLC: Seeing Beyond Age

PS01.02 Thoracic Oncology Clinical Trial Eligibility Criteria: Ongoing Increase in Recent Years

PS01.03 Referral Practices of Medical Oncologists to Palliative Care For Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
4:55 - 5:05pm

Poster Discussant: Mary Jo Fidler

Highlighted Posters:

**PS01.04** A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer

**PS01.05** Early and Persistent Oligoclonal T Cell Expansion Correlates with Durable Response to Anti-PD1 Therapy in NSCLC

**PS01.06** Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma

**PS01.07** Geographical Distribution of Lung Cancer Mortality Worldwide

**PS01.08** ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients With ECOG PS of 2

5:05pm - 6:30pm Poster Viewing and Reception

6:30pm - 8:30pm Dinner Symposium Sponsored by Astra Zeneca

Saturday, September 24, 2016

7:00am - 1:00pm Registration

7:00am - 8:00am Breakfast Symposium Sponsored by Astra Zeneca

8:00am - 9:30am Highlighted Oral Session 2
8:00am - 8:20am LBA1 NSCLC in Women vs. Men, Tobacco-Exposed or Not – 2016 Perspective (including first results from SWOG S0424) Kathy Albain

8:20am - 8:30am Oral02.01 Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC Todd M. Bauer

8:30am - 8:40am Oral02.02 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis James Yao

8:40am - 8:50am Discussant Corey Langer

8:50am - 9:00am Oral02.03 Robust Correlation between Metabolic Responses Measured with 18F-FDG PET Soon after Therapy and Clinical Outcome in Lung Cancer Noah C. Choi

9:00am - 9:10am Oral02.04 Predictors of Adverse Perioperative Outcome Following Lobectomy: A Population Based Analysis Mohamed Kamel

9:10am - 9:20am Oral02.05 Understanding Internal Differences in N-category-Stratified Non-Small Cell Lung Cancer (NSCLC) Survival Raymond Osarogiagbon

9:20am - 9:30am Discussant Jessica Donington

9:30am - 9:45am Break

9:45am - 10:30am Session 3A/3B

Breakout Session 3A EGFR/ALK Resistance Leora Horn (Discussant)

Mini01.01 Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases Results of ASCEND 1 and 3 Alice Shaw

Mini01.02 Response and plasma genotyping from phase I/II trial of Ensartinib (X-396) in patients (pts) with ALK+ NSCLC Leora Horn
**Mini01.03** Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC

Todd M. Bauer

**Mini01.04** ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next-Generation Genotyping from ctDNA

Xiaomin Niu

**Mini01.05** RALPB1 Mediate ALK Resistance in Non-Small Cell Lung Cancer; MD

Mohamed Shanshal

**Breakout Session 3B  Surgery  Jessica Donington (Discussant)**

**Mini01.06** Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non-small Cell Lung Cancer Progression and Clinical Outcome

Imad Tarhoni

**Mini01.07** Predictors of Conversion to Thoracotomy in VATS Lobectomy Patients

M. Rahouma

**Mini01.08** Disparities in the Management of Patients with Stage I Small Cell Lung Cancer (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis

Zaheer Ahmed

**Mini01.09** Outcomes of Early Stage Large Cell Neuroendocrine Lung Carcinoma (LCNELC): A National Cancer Database (NCDB) Analysis

Lara Kujtan

**Mini01.10** Diverse Populations may be Underrepresented in Community Lung Cancer Screening Programs

Bretta McCall

**10:30am-11:15am  Session 4A/4B**

**Breakout Session 4A  Radiation  Laurie Gaspar (Discussant)**

**Mini01.11** Radiotherapy plus EGFR TKIs for Brain Metastasis in EGFR-mutant Non-Small Cell Lung Cancer: a Retrospective Analysis of a Single Institution

Jiexia Zhang

**Mini01.12** Angiogenesis Biomarkers are Associated with Progression Free Survival in Non-Small Cell Lung Cancer Treated with SBRT

Gaurav Marwaha
Mini01.13 Prediction of Lung Toxicity in the Definitive Radiotherapy of Non-Small-Cell Lung Cancer using Clinical, Dosimetric and Biologic Factors
Peter Hawkins

Mini01.14 Self-Efficacy & Decisions in Lung Cancer: Early Stage Lung Cancer Comparative Effectiveness Research Consortium Results
Charles Thomas, Jr

Mini01.15 Prophylactic cranial irradiation (PCI) for Limited Small Cell Lung Cancer (LSCLC): An IASLC physician survey
Laurie Gaspar

Breakout Session 4B Outcomes/QoL
Natasha Leighl (Discussant)

Mini01.16 Not So Easy : Readability Assessment of Patient Education Material on Non-Small Cell Lung Cancer Immunotherapy
Supreet Kaur

Mini01.17 Project Reach: Piloting a Risk-Tailored Smoking Cessation Intervention for Lung Screening
Inga Lennes

Mini01.18 Integration of Tobacco Cessation in a Lung Cancer Screening Program
Matthew A. Steliga

Mini01.19 Cost Analysis of Pemetrexed-Platinum with Maintenance vs. Paclitaxel-Carboplatin-Bevacizumab with Maintenance in Patients with Lung Cancer
Kristin Sheffield

Mini01.20 Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC
Michael Thomas

11:25am - 12:30pm
Multidisciplinary Tumor Board – State of the Art
Samir Witta
Corey Langer
Philip Hoffman